Time Period, mo | N* | No. Fractures/10,000 pt-yrs | Total No. Fractures | Patients with ≥ 1 Fracture, n (%)* | Odds of Fracture** (95% CI) | OR**† (95% CI) | p |
---|---|---|---|---|---|---|---|
GC users | |||||||
0 to < 6 | 156 | 1416 | 11 | 10 (6.4) | 0.065 (0.033, 0.131) | — | |
6 to < 12 | 152 | 140 | 1 | 1 (0.7) | 0.006 (0.001, 0.047) | 0.10 (0.01, 0.78) | 0.028 |
12 to < 18 | 137 | 153 | 1 | 1 (0.7) | 0.007 (0.001, 0.051) | 0.11 (0.01, 0.83) | 0.033 |
Total | 156 | 13†† | 11 (7.1) | ||||
GC nonusers | |||||||
0 to < 6 | 753 | 427 | 16 | 14 (1.9) | 0.018 (0.010, 0.031) | — | |
6 to < 12 | 715 | 413 | 14 | 13 (1.8) | 0.018 (0.010, 0.031) | 0.98 (0.45, 2.11) | 0.955 |
12 to < 18 | 666 | 479 | 15 | 13 (2.0) | 0.019 (0.011, 0.033) | 1.04 (0.49, 2.18) | 0.928 |
Total | 753 | 45# | 39 (5.2) |
↵* As some patients experienced a fracture in more than 1 time period, the total was not the sum of patients with a fracture in each period.
↵** Model adjusted by age, prior bisphosphonate use, and fracture in last 12 months before starting teriparatide.
↵† Compared with 0 to < 6-month interval after teriparatide was stopped.
↵†† Four vertebral and 9 nonvertebral fractures.
↵# Eleven vertebral and 34 nonvertebral fractures.